SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
Turnover
51.02%
1-Year Est. Return
524.65%
This Fund
S&P 500
This Quarter
Est. Return
+2.41%
1 Year Est. Return
+524.65%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.09%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$107M
(-31%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-20.81%
Top 10 Holdings %
Top 10 Hldgs %
35.16%
Holding
111
New
21
Increased
25
Reduced
24
Closed
39
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merus
MRUS
|
+$6.87M |
| 2 |
89bio
ETNB
|
+$5.71M |
| 3 |
KalVista Pharmaceuticals
KALV
|
+$5.4M |
| 4 |
Cogent Biosciences
COGT
|
+$5.12M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$5.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$10.9M |
| 2 |
Morphic Holding, Inc. Common Stock
MORF
|
+$10.4M |
| 3 |
Immunovant
IMVT
|
+$9.22M |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$5.8M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
+$5.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.86% |
| 2 | Miscellaneous | 8.14% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Merus
MRUS
| $12.3M | 5.08% |
668,784
+394,080
| +143% | +$6.87M |
2021 Q1
8 quarters
|
|
2
MacroGenics
MGNX
$211M
| $9.76M | 4.03% |
1,361,809
+749,334
| +122% | +$4.51M |
2022 Q3
2 quarters
|
|
|
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
| $9.67M | 3.99% |
2,793,748
+388,388
| +16% | +$1.64M |
2021 Q2
7 quarters
|
|
4
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $8.28M | 3.42% |
2,689,301
+459,301
| +21% | +$2.75M |
2021 Q4
5 quarters
|
|
5
Oric Pharmaceuticals
ORIC
$1.2B
| $8.18M | 3.38% |
1,435,945
+199,649
| +16% | +$1.04M |
2022 Q2
3 quarters
|
|
6
DELISTED
Terns Pharmaceuticals
TERN
| $7.91M | 3.26% |
667,922
-32,078
| -5% | -$307K |
2022 Q3
2 quarters
|
|
7
DELISTED
Akero Therapeutics
AKRO
| $7.75M | 3.2% |
202,561
+30,461
| +18% | +$1.36M |
2022 Q2
3 quarters
|
|
8
DELISTED
Nuvalent
NUVL
| $7.35M | 3.03% |
281,533
-21,430
| -7% | -$634K |
2022 Q3
2 quarters
|
|
|
BLU
9
DELISTED
BELLUS Health Inc.
BLU
| $7.2M | 2.97% |
1,000,000
-707,370
| -41% | -$5.49M |
2021 Q2
7 quarters
|
|
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.77M | 2.79% |
125,035
-15,331
| -11% | -$741K |
2020 Q4
9 quarters
|
|
|
11
DELISTED
89bio
ETNB
| $6.67M | 2.76% |
+438,215
| New | +$5.71M |
2023 Q1
0 quarters
|
|
12
Viking Therapeutics
VKTX
$3.24B
| $6.33M | 2.61% |
+380,000
| New | +$3.93M |
2023 Q1
0 quarters
|
|
|
13
Cogent Biosciences
COGT
$4.88B
| $6.25M | 2.58% |
579,264
+400,264
| +224% | +$5.12M |
2020 Q4
9 quarters
|
|
|
14
Karyopharm Therapeutics
KPTI
$7.14M
| $6M | 2.48% |
+102,762
| New | +$5.07M |
2023 Q1
0 quarters
|
|
|
15
DELISTED
KalVista Pharmaceuticals
KALV
| $5.69M | 2.35% |
+723,544
| New | +$5.4M |
2023 Q1
0 quarters
|
|
16
Schrodinger
SDGR
$1.87B
| $5.6M | 2.31% |
212,825
+104,825
| +97% | +$2.49M |
2022 Q4
1 quarter
|
|
17
CALL
Pliant Therapeutics
PLRX
$54.7M
| $5.31M | 2.19% |
+199,600
| New | +$5.68M |
2023 Q1
0 quarters
|
|
18
CALL
Aclaris Therapeutics
ACRS
$498M
| $5.27M | 2.18% |
+651,400
| New | +$8.27M |
2023 Q1
0 quarters
|
|
19
Gilead Sciences
GILD
$190B
| $4.99M | 2.06% |
60,130
+8,168
| +16% | +$677K |
2022 Q4
1 quarter
|
|
20
BioCryst Pharmaceuticals
BCRX
$2.06B
| $4.82M | 1.99% |
577,757
+305,584
| +112% | +$2.94M |
2022 Q1
4 quarters
|
|
21
Veracyte
VCYT
$3.5B
| $4.68M | 1.93% |
209,653
+9,653
| +5% | +$233K |
2021 Q1
8 quarters
|
|
22
Pharvaris
PHVS
$2.11B
| $4.51M | 1.86% |
559,387
+459,387
| +459% | +$4.04M |
2022 Q4
1 quarter
|
|
23
CALL
DELISTED
Immunogen Inc
IMGN
| $4.33M | 1.79% |
1,128,200
+896,200
| +386% | +$3.82M |
2022 Q4
1 quarter
|
|
24
United Therapeutics
UTHR
$23.2B
| $4.16M | 1.72% |
18,578
+2,530
| +16% | +$624K |
2020 Q4
9 quarters
|
|
25
Vertex Pharmaceuticals
VRTX
$126B
| $4.15M | 1.71% |
13,181
+1,797
| +16% | +$539K |
2021 Q4
5 quarters
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
RAM
JWBC
Silverarc Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Silverarc Capital Management held 111 positions worth $242M, down 31% from $350M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Silverarc Capital Management withdrew a net $50.4M in Q1 2023, closing 39 positions and reducing 24 holdings. Its most notable exit was Immunovant, an estimated $9.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Silverarc Capital Management opened a new position in 89bio worth $6.67M.
- Silverarc Capital Management's largest Q1 2023 buy was 89bio: 438,215 shares worth $6.67M.
- Silverarc Capital Management added most to Merus in Q1 2023, an estimated $6.87M increase.
- Silverarc Capital Management's biggest Q1 2023 reduction was Madrigal Pharmaceuticals, cutting an estimated $10.9M.
- Silverarc Capital Management fully exited Immunovant in Q1 2023, selling an estimated $9.22M.
- Silverarc Capital Management's ten largest holdings make up 35% of its $242M portfolio in Q1 2023.
- Silverarc Capital Management opened 21 new positions and closed 39 in Q1 2023.
- Silverarc Capital Management's portfolio value fell 31% quarter-over-quarter to $242M.
Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.